During the recent session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares were 0.75 million, with the beta value of the company hitting 1.07. The 52-week high for the LXRX share is $2.47, that puts it down -648.48 from that peak though still a striking 15.15% gain since the share price plummeted to a 52-week low of $0.28. The company’s market capitalization is $118.21M, and the average intraday trading volume over the past 10 days was 4.32 million shares, and the average trade volume was 6.31 million shares over the past three months.
Lexicon Pharmaceuticals Inc (LXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.17. LXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.1.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Lexicon Pharmaceuticals Inc (LXRX) registered a -0.61% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.61% in intraday trading to $0.33, hitting a weekly high. The stock’s 5-day price performance is -5.19%, and it has moved by -53.72% in 30 days. Based on these gigs, the overall price performance for the year is -85.53%. The short interest in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 39.26 million shares and it means that shorts have 4.04 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 94.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, LXRX is trading at a discount of -1718.18% off the target high and -1718.18% off the low.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -69.95% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.26M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 1.33M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.13M and 1.65M respectively. In this case, analysts expect current quarter sales to grow by 11.73% and then drop by -19.25% in the coming quarter.
LXRX Dividends
Lexicon Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Mar-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Lexicon Pharmaceuticals Inc insiders own 1.19% of total outstanding shares while institutional holders control 84.11%, with the float percentage being 85.13%. ARTAL GROUP S.A. is the largest shareholder of the company, while 168.0 institutions own stock in it. As of 2024-06-30, the company held over 175.1 million shares (or 56.3318% of all shares), a total value of $294.17 million in shares.
The next largest institutional holding, with 38.69 million shares, is of FMR LLC’s that is approximately 12.4462% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.99 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lexicon Pharmaceuticals Inc (LXRX) shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund. Data provided on Jan 31, 2025 indicates that Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund owns about 16.86 shares. This amounts to just over 4.66 percent of the company’s overall shares, with a $5.52 million market value. The same data shows that the other fund manager holds slightly less at 5.54, or about 1.53% of the stock, which is worth about $1.81 million.
